Glucagon‐like peptide‐1 receptor agonists and mental health: A meta‐analysis of randomized controlled trials

Documenti analoghi

• Weight‐reducing treatments are associated with an improvement in depression, functional health status, and quality of life: A meta‐analysis of randomized controlled trials
  di: Giovanni Antonio Silverii, et al.
  Pubblicazione: (2025)
• Glucagon‐like peptide‐1 receptor agonists lower risk of cardiovascular and non‐cardiovascular mortality: A meta‐analysis of eleven cardiovascular outcome trials
  di: Yu Mi Kang, et al.
  Pubblicazione: (2025)
• Glucagon‐like peptide 1 receptor agonist for peripheral artery disease: Is it time to proceed?
  di: Dario Giugliano, et al.
  Pubblicazione: (2025)
• Risk of thyroid cancer related to glucagon‐like peptide‐1 receptor agonists: A systematic review with meta‐analysis of harms of randomized controlled trials
  di: Lucas Duchemin, et al.
  Pubblicazione: (2025)
• Efficacy and safety of a bio ‐absorbable antibiotic delivery in calcium sulphate granules for the treatment of osteomyelitis in patients with diabetic foot: A randomized, double blinded, controlled clinical study The BIG D‐ FOOT study
  di: Matteo Monami, et al.
  Pubblicazione: (2025)